Regeneron Pharmaceuticals Company Profile (NASDAQ:REGN)

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals logoRegeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company's segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. Its marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. Its other products include Sarilumab (REGN88), Dupilumab (REGN668), REGN2222, Fasinumab (REGN475), REGN2810, REGN2176-3, Evinacumab (REGN1500) and REGN1908-1909.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: REGN
  • CUSIP: 75886F10
Key Metrics:
  • Previous Close: $406.36
  • 50 Day Moving Average: $405.75
  • 200 Day Moving Average: $390.56
  • 52-Week Range: $329.09 - $592.59
  • Trailing P/E Ratio: 63.39
  • Foreward P/E Ratio: 27.99
  • P/E Growth: 2.00
  • Market Cap: $42.52B
  • Outstanding Shares: 104,633,000
  • Beta: 1.24
  • Net Margins: 15.65%
  • Return on Equity: 23.77%
  • Return on Assets: 15.35%
  • Debt-to-Equity Ratio: 0.09%
  • Current Ratio: 3.37%
  • Quick Ratio: 3.04%
Additional Links:
Companies Related to Regeneron Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) (?)
Ratings Breakdown: 1 Sell Rating, 12 Hold Ratings, 10 Buy Ratings
Consensus Rating:Hold (Score: 2.39)
Consensus Price Target: $472.45 (16.26% upside)

Analysts' Ratings History for Regeneron Pharmaceuticals (NASDAQ:REGN)
DateFirmActionRatingPrice TargetDetails
9/27/2016Goldman Sachs Group Inc.Reiterated RatingBuy$521.00View Rating Details
9/23/2016Roth CapitalReiterated RatingBuy$520.00View Rating Details
9/23/2016Robert W. BairdReiterated RatingNeutral$448.00View Rating Details
9/21/2016Leerink SwannReiterated RatingBuy$530.00View Rating Details
9/20/2016Piper Jaffray Cos.Reiterated RatingHold$447.00View Rating Details
8/17/2016Jefferies GroupReiterated RatingHoldView Rating Details
8/6/2016RBC Capital MarketsReiterated RatingBuyView Rating Details
8/5/2016Brean CapitalReiterated RatingBuy$489.00View Rating Details
8/5/2016Canaccord GenuityReiterated RatingHold$450.00View Rating Details
8/5/2016Cowen and CompanyReiterated RatingHold$430.00View Rating Details
7/12/2016BTIG ResearchReiterated RatingHoldView Rating Details
6/30/2016Sanford C. BernsteinReiterated RatingBuyView Rating Details
6/23/2016Citigroup Inc.Reiterated RatingBuy$470.00View Rating Details
6/8/2016Chardan CapitalDowngradeSell$325.00View Rating Details
6/8/2016Wells Fargo & Co.Reiterated RatingHoldView Rating Details
4/8/2016Morgan StanleyLower Price Target$436.00 -> $415.00View Rating Details
4/1/2016Credit Suisse Group AGReiterated RatingHold$481.00View Rating Details
3/17/2016SunTrust Banks Inc.Lower Price TargetNeutral$450.00 -> $410.00View Rating Details
3/15/2016GabelliInitiated CoverageBuy$574.00View Rating Details
3/13/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details
2/11/2016Bank of America Corp.Reiterated RatingBuy$649.00 -> $525.00View Rating Details
2/10/2016Royal Bank Of CanadaReiterated RatingOutperform$676.00 -> $668.00View Rating Details
2/10/2016Barclays PLCLower Price TargetEqual Weight$610.00 -> $425.00View Rating Details
8/31/2015Raymond James Financial Inc.Initiated CoverageOutperform$615.00View Rating Details
8/6/2015ArgusBoost Price TargetBuy$560.00 -> $660.00View Rating Details
8/4/2015Deutsche Bank AGReiterated RatingBuy$650.00 -> $720.00View Rating Details
7/27/2015BMO Capital MarketsReiterated RatingMarket Perform$381.00 -> $494.00View Rating Details
7/22/2015Northland SecuritiesInitiated CoverageMarket Perform$560.00View Rating Details
10/2/2014GuggenheimInitiated CoverageBuy$432.00View Rating Details
(Data available from 9/29/2014 forward)


Earnings History for Regeneron Pharmaceuticals (NASDAQ:REGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216$2.65$2.82$1.24 billion$1.21 billionViewN/AView Earnings Details
5/5/2016Q116$2.58$2.57$1.18 billion$1.20 billionViewN/AView Earnings Details
2/9/2016Q415$3.40$2.83$1.17 billion$1.10 billionViewListenView Earnings Details
11/4/2015Q315$2.62$3.47$1.05 billion$1.14 billionViewListenView Earnings Details
8/4/2015Q215$2.77$2.89$887.03 million$999.00 millionViewListenView Earnings Details
5/7/2015Q115$2.50$2.88$820.30 million$870.00 millionViewN/AView Earnings Details
2/10/2015Q414$2.78$2.79$775.42 million$802.00 millionViewN/AView Earnings Details
11/4/2014Q314$2.57$2.52$733.04 million$726.00 millionViewN/AView Earnings Details
8/5/2014Q214$2.30$2.47$647.99 million$666.00 millionViewN/AView Earnings Details
5/8/2014Q114$0.94$0.58$609.04 million$626.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.97$2.24$579.17 million$610.00 millionViewN/AView Earnings Details
11/5/2013Q313$0.92$2.40$501.93 million$597.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.92$1.73$470.63 million$458.00 millionViewN/AView Earnings Details
5/3/2013Q1 2013$1.46$1.78$424.26 million$440.00 millionViewN/AView Earnings Details
2/14/2013Q4 2012$1.11$1.47$392.64 million$415.00 millionViewN/AView Earnings Details
10/24/2012$1.14$1.89ViewN/AView Earnings Details
7/25/2012$0.45$0.90ViewN/AView Earnings Details
4/26/2012($0.33)$0.37ViewN/AView Earnings Details
2/13/2012($0.60)($0.37)ViewN/AView Earnings Details
7/28/2011($0.40)($0.69)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)
Current Year EPS Consensus Estimate: $11.00 EPS
Next Year EPS Consensus Estimate: $14.52 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$1.47$2.49$1.98
Q2 20161$1.62$1.62$1.62
Q3 20161$1.69$1.69$1.69
Q4 20162$1.77$2.79$2.28
(Data provided by Zacks Investment Research)


Dividend History for Regeneron Pharmaceuticals (NASDAQ:REGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 68.16%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/29/2016Joseph L GoldsteinDirectorSell2,125$425.00$903,125.00View SEC Filing  
6/14/2016SanofiMajor ShareholderBuy64,731$363.86$23,553,021.66View SEC Filing  
5/24/2016Arthur F RyanDirectorSell1,000$396.64$396,640.00View SEC Filing  
5/18/2016Plew Daniel P VanEVPSell4,413$385.77$1,702,403.01View SEC Filing  
4/6/2016Joseph L GoldsteinDirectorSell2,000$425.00$850,000.00View SEC Filing  
3/21/2016Joseph L GoldsteinDirectorSell2,000$375.00$750,000.00View SEC Filing  
2/17/2016SanofiMajor ShareholderBuy161,157$392.46$63,247,676.22View SEC Filing  
1/12/2016SanofiMajor ShareholderBuy83,938$465.04$39,034,527.52View SEC Filing  
12/29/2015Douglas S. MccorkleVPSell3,954$552.08$2,182,924.32View SEC Filing  
12/10/2015Michael S. BrownDirectorSell3,000$546.45$1,639,350.00View SEC Filing  
12/2/2015George YancopoulosinsiderSell43,348$549.03$23,799,352.44View SEC Filing  
11/18/2015P Roy VagelosChairmanSell17,240$587.90$10,135,396.00View SEC Filing  
11/10/2015Plew Daniel P. VanSVPSell5,123$554.85$2,842,496.55View SEC Filing  
11/9/2015Neil StahlEVPSell42,101$561.45$23,637,606.45View SEC Filing  
11/3/2015P Roy VagelosChairmanSell17,242$580.19$10,003,635.98View SEC Filing  
11/2/2015George YancopoulosinsiderSell43,348$571.61$24,778,150.28View SEC Filing  
10/6/2015SanofiMajor ShareholderBuy80,538$459.71$37,024,123.98View SEC Filing  
9/23/2015SanofiMajor ShareholderBuy147,209$534.67$78,708,236.03View SEC Filing  
9/21/2015Michael S. BrownDirectorSell3,000$551.55$1,654,650.00View SEC Filing  
9/17/2015Charles A. BakerDirectorSell5,000$550.00$2,750,000.00View SEC Filing  
8/14/2015Peter PowchikSVPSell23,485$573.38$13,465,829.30View SEC Filing  
7/15/2015Joseph L GoldsteinDirectorSell2,000$550.00$1,100,000.00View SEC Filing  
6/22/2015Joseph L GoldsteinDirectorSell2,000$526.85$1,053,700.00View SEC Filing  
5/27/2015Robert Alexander IngramDirectorSell1,379$513.39$707,964.81View SEC Filing  
5/26/2015Plew Daniel P VanSVPSell18,370$508.42$9,339,675.40View SEC Filing  
5/22/2015Douglas S MccorkleVPSell13,000$515.60$6,702,800.00View SEC Filing  
5/22/2015Joseph L GoldsteinDirectorSell4,000$514.28$2,057,120.00View SEC Filing  
5/15/2015Michael S BrownDirectorSell5,000$495.00$2,475,000.00View SEC Filing  
3/25/2015Charles A BakerDirectorSell5,000$454.96$2,274,800.00View SEC Filing  
3/24/2015Michael S AbermanSVPSell4,843$478.99$2,319,748.57View SEC Filing  
3/18/2015Michael S AbermanSVPSell3,442$465.00$1,600,530.00View SEC Filing  
3/17/2015Robert J TerifaySVPSell10,993$451.01$4,957,952.93View SEC Filing  
3/16/2015Joseph J LarosaSVPSell18,311$450.00$8,239,950.00View SEC Filing  
2/27/2015Douglas S MccorkleVPSell3,000$416.24$1,248,720.00View SEC Filing  
2/26/2015Marc Tessier-LavigneDirectorSell3,000$421.95$1,265,850.00View SEC Filing  
2/24/2015Robert J TerifaySVPSell11,173$423.67$4,733,664.91View SEC Filing  
2/23/2015Plew Daniel P VanSVPSell9,431$427.82$4,034,770.42View SEC Filing  
2/20/2015Joseph L GoldsteinDirectorSell5,000$423.65$2,118,250.00View SEC Filing  
2/17/2015Michael S AbermanSVPSell3,692$404.46$1,493,266.32View SEC Filing  
1/2/2015Leonard S SchleiferCEOSell1,500$410.58$615,870.00View SEC Filing  
1/2/2015Peter PowchikSVPSell10,822$414.08$4,481,173.76View SEC Filing  
12/24/2014SanofiMajor ShareholderBuy201,459$393.21$79,215,693.39View SEC Filing  
12/16/2014Douglas S MccorkleVPSell8,486$410.15$3,480,532.90View SEC Filing  
11/24/2014Alfred G GilmanDirectorSell40,000$408.44$16,337,600.00View SEC Filing  
11/24/2014Neil StahlSVPSell5,307$412.93$2,191,419.51View SEC Filing  
11/18/2014Robert J TerifaySVPSell22,362$405.79$9,074,275.98View SEC Filing  
11/13/2014Plew Daniel P VanSVPSell8,575$399.34$3,424,340.50View SEC Filing  
11/12/2014Joseph L GoldsteinDirectorSell5,000$398.31$1,991,550.00View SEC Filing  
11/12/2014Leonard S SchleiferCEOSell45,817$400.30$18,340,545.10View SEC Filing  
10/28/2014Leonard S SchleiferCEOSell69,112$404.01$27,921,939.12View SEC Filing  
10/24/2014Michael S BrownDirectorSell5,000$399.00$1,995,000.00View SEC Filing  
10/24/2014Murray A GoldbergSVPSell26,788$400.70$10,733,951.60View SEC Filing  
9/16/2014SanofiMajor ShareholderBuy31,717$349.26$11,077,479.42View SEC Filing  
9/15/2014SanofiMajor ShareholderBuy140,632$345.15$48,539,134.80View SEC Filing  
9/10/2014P Roy VagelosChairmanSell10,328$350.07$3,615,522.96View SEC Filing  
8/27/2014Joseph L GoldsteinDirectorSell2,000$350.31$700,620.00View SEC Filing  
8/19/2014Michael S AbermanVPSell3,611$350.00$1,263,850.00View SEC Filing  
8/18/2014Douglas S MccorkleVPSell5,875$353.00$2,073,875.00View SEC Filing  
8/15/2014Michael S BrownDirectorSell3,000$349.20$1,047,600.00View SEC Filing  
8/14/2014Joseph L GoldsteinDirectorSell2,000$347.65$695,300.00View SEC Filing  
8/13/2014P Roy VagelosChairmanSell8,028$340.01$2,729,600.28View SEC Filing  
8/11/2014Neil StahlSVPSell11,646$339.96$3,959,174.16View SEC Filing  
8/11/2014P Roy VagelosChairmanSell11,972$340.11$4,071,796.92View SEC Filing  
8/8/2014Neil StahlSVPSell2,841$340.60$967,644.60View SEC Filing  
8/7/2014Plew Daniel P VanSVPSell6,806$338.37$2,302,946.22View SEC Filing  
8/6/2014Joseph L GoldsteinDirectorSell2,000$331.20$662,400.00View SEC Filing  
7/15/2014SanofiMajor ShareholderBuy129,100$314.92$40,656,172.00View SEC Filing  
7/14/2014SanofiMajor ShareholderBuy300,000$316.80$95,040,000.00View SEC Filing  
7/10/2014SanofiMajor ShareholderBuy175,000$311.08$54,439,000.00View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy348,000$309.76$107,796,480.00View SEC Filing  
7/7/2014SanofiMajor ShareholderBuy356,700$312.37$111,422,379.00View SEC Filing  
7/2/2014SanofiMajor ShareholderBuy212,400$307.25$65,259,900.00View SEC Filing  
7/1/2014SanofiMajor ShareholderBuy212,400$300.20$63,762,480.00View SEC Filing  
6/30/2014SanofiMajor ShareholderBuy262,400$281.17$73,779,008.00View SEC Filing  
5/23/2014Plew Daniel VanSVPSell5,369$295.93$1,588,848.17View SEC Filing  
5/19/2014Sanofimajor shareholderBuy190,751$300.04$57,232,930.04View SEC Filing  
3/28/2014Sanofimajor shareholderBuy306,945$306.73$94,149,239.85View SEC Filing  
3/27/2014Sanofimajor shareholderBuy306,945$311.01$95,462,964.45View SEC Filing  
3/24/2014Charles BakerDirectorSell15,000$302.67$4,540,050.00View SEC Filing  
3/24/2014Sanofimajor shareholderBuy306,945$307.91$94,511,434.95View SEC Filing  
3/21/2014Sanofimajor shareholderBuy305,115$321.22$98,009,040.30View SEC Filing  
3/20/2014Sanofimajor shareholderBuy67,703$328.33$22,228,925.99View SEC Filing  
3/17/2014Michael BrownDirectorSell2,000$334.29$668,580.00View SEC Filing  
3/17/2014Sanofimajor shareholderBuy115,711$328.46$38,006,435.06View SEC Filing  
3/12/2014Sanofimajor shareholderBuy220,995$334.69$73,964,816.55View SEC Filing  
3/11/2014Sanofimajor shareholderBuy380,532$330.41$125,731,578.12View SEC Filing  
3/7/2014Sanofimajor shareholderBuy150,277$328.72$49,399,055.44View SEC Filing  
3/3/2014Sanofimajor shareholderBuy251,594$338.12$85,068,963.28View SEC Filing  
2/27/2014Michael BrownDirectorSell1,000$335.00$335,000.00View SEC Filing  
2/25/2014Joseph GoldsteinDirectorSell1,000$338.86$338,860.00View SEC Filing  
2/25/2014Murray GoldbergSVPSell11,871$339.55$4,030,798.05View SEC Filing  
2/21/2014Alfred GilmanDirectorSell5,000$340.00$1,700,000.00View SEC Filing  
2/21/2014Murray GoldbergSVPSell21,258$336.51$7,153,529.58View SEC Filing  
2/20/2014Joseph GoldsteinDirectorSell1,000$326.99$326,990.00View SEC Filing  
2/18/2014Michael AbermanVPSell3,648$331.42$1,209,020.16View SEC Filing  
2/18/2014Robert TerifaySVPSell12,865$332.68$4,279,928.20View SEC Filing  
2/13/2014Neil StahlSVPSell22,612$318.82$7,209,157.84View SEC Filing  
2/12/2014George YancopoulosInsiderSell88,987$320.33$28,505,205.71View SEC Filing  
2/12/2014Joseph GoldsteinDirectorSell1,000$320.62$320,620.00View SEC Filing  
2/11/2014Alfred GilmanDirectorSell5,000$320.00$1,600,000.00View SEC Filing  
2/11/2014Douglas MccorkleVPSell5,819$325.00$1,891,175.00View SEC Filing  
2/11/2014P Roy VagelosChairmanSell11,475$325.10$3,730,522.50View SEC Filing  
2/7/2014Sanofimajor shareholderBuy168,511$286.78$48,325,584.58View SEC Filing  
2/5/2014Sanofimajor shareholderBuy397,264$284.12$112,870,647.68View SEC Filing  
2/3/2014Sanofimajor shareholderBuy208,972$283.78$59,302,074.16View SEC Filing  
1/28/2014Sanofimajor shareholderBuy157,920$275.90$43,570,128.00View SEC Filing  
1/14/2014Alfred GilmanDirectorSell5,000$300.00$1,500,000.00View SEC Filing  
1/14/2014Douglas MccorkleVPSell4,000$290.00$1,160,000.00View SEC Filing  
1/2/2014Peter PowchikSVPSell20,668$274.77$5,678,946.36View SEC Filing  
12/20/2013Peter PowchikSVPSell9,133$270.21$2,467,827.93View SEC Filing  
11/26/2013George SingDirectorSell10,000$295.00$2,950,000.00View SEC Filing  
11/6/2013Joseph GoldsteinDirectorSell1,000$300.74$300,740.00View SEC Filing  
9/19/2013Leonard SchleiferCEOSell102,949$302.67$31,159,573.83View SEC Filing  
9/19/2013P Roy VagelosChairmanSell145,356$302.86$44,022,518.16View SEC Filing  
9/18/2013Plew Daniel VanSVPSell23,977$303.17$7,269,107.09View SEC Filing  
9/18/2013William RobertsVPSell15,000$304.00$4,560,000.00View SEC Filing  
9/9/2013Leonard S SchleiferCEOSell5,000$275.47$1,377,350.00View SEC Filing  
8/23/2013Joseph GoldsteinDirectorSell1,000$238.29$238,290.00View SEC Filing  
6/10/2013Charles A BakerDirectorSell15,000$251.84$3,777,600.00View SEC Filing  
5/31/2013Arthur F RyanDirectorSell2,500$249.55$623,875.00View SEC Filing  
5/28/2013Joseph L GoldsteinDirectorSell4,000$252.20$1,008,800.00View SEC Filing  
5/21/2013Murray A GoldbergCFOSell66,835$259.74$17,359,722.90View SEC Filing  
5/17/2013Michael S BrownDirectorSell15,000$275.19$4,127,850.00View SEC Filing  
5/14/2013Michael S AbermanVPSell5,529$279.61$1,545,963.69View SEC Filing  
5/13/2013Neil StahlSVPSell23,038$276.88$6,378,761.44View SEC Filing  
5/10/2013George L SingDirectorSell5,000$270.00$1,350,000.00View SEC Filing  
5/8/2013Robert J TerifaySVPSell8,231$261.23$2,150,184.13View SEC Filing  
5/6/2013P Roy VagelosChairmanSell12,018$263.15$3,162,536.70View SEC Filing  
11/27/2012P Roy VagelosChairmanSell64,753$175.22$11,346,020.66View SEC Filing  
11/26/2012Charles A BakerDirectorSell15,000$173.87$2,608,050.00View SEC Filing  
11/14/2012Michael S BrownDirectorSell7,000$147.03$1,029,210.00View SEC Filing  
11/1/2012Arthur F RyanDirectorSell10,000$145.57$1,455,700.00View SEC Filing  
9/6/2012Charles A BakerDirectorSell15,000$150.00$2,250,000.00View SEC Filing  
8/23/2012George L SingDirectorSell10,000$140.50$1,405,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Regeneron Pharmaceuticals (NASDAQ:REGN)
DateHeadline logoWhy Investors Are Paying a Premium for Regeneron Pharmaceuticals, Inc. - Motley Fool (NASDAQ:REGN) - September 29 at 6:56 PM logoWhy Investors Are Paying a Premium for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - September 29 at 4:55 PM logoHow Does Regeneron’s 2016 Guidance Look? (NASDAQ:REGN) - September 29 at 12:08 PM logoWhat’s the Word on Street for Vertex? (NASDAQ:REGN) - September 28 at 12:14 PM
News IconTop Gainers of the Day: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) from Biotechnology (NASDAQ:REGN) - September 27 at 6:54 PM
News IconIs Regeneron Pharmaceuticals, Inc.(NASDAQ: REGN), a large market cap stock a smart buy? - The Daily Leicester (NASDAQ:REGN) - September 27 at 11:38 AM logoFDA Grants Priority Review For Dupilumab BLA FROM Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Sanofi SA ... - Market Exclusive (NASDAQ:REGN) - September 27 at 11:38 AM logoRegeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : REGN-US : September 27, 2016 (NASDAQ:REGN) - September 27 at 11:38 AM logoStock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Sanofi Announce Dupilumab Biologics License ... - Smarter Analyst (NASDAQ:REGN) - September 26 at 7:03 PM logoRegeneron-Sanofi Could Beat Pfizer, Roche, AstraZeneca On Eczema (NASDAQ:REGN) - September 26 at 7:03 PM logoRegeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA (NASDAQ:REGN) - September 26 at 11:50 AM logoStock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Sanofi Announce ... (NASDAQ:REGN) - September 26 at 11:50 AM logoSanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA (NASDAQ:REGN) - September 26 at 11:50 AM logoRegeneron Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for REGN (NASDAQ:REGN) - September 24 at 11:26 AM
News IconRegeneron Pharmaceuticals Inc: 40%+ Returns if REGN Stock Does THIS - Profit Confidential (NASDAQ:REGN) - September 23 at 6:32 PM
News IconRegeneron Pharmaceuticals Inc: 40%+ Returns if REGN Stock Does THIS (NASDAQ:REGN) - September 23 at 11:44 AM
News IconCan Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Grow Their Earnings? Analyst Perspectives in Scope - Yankee Analysts (NASDAQ:REGN) - September 22 at 6:43 PM logoStock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Teva Announce Global Collaboration to Develop ... - Smarter Analyst (NASDAQ:REGN) - September 22 at 6:43 PM logoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Affirmed at Buy by Roth Capital: Here's Why - TCC (NASDAQ:REGN) - September 22 at 6:43 PM
News IconBiotech Stocks To Put On Your Watch List: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Alexion ... - The Voice Registrar (NASDAQ:REGN) - September 22 at 6:43 PM logo[$$] Teva, Allergan Pump Up the Pipelines (NASDAQ:REGN) - September 22 at 11:50 AM logoRegeneron to Collaborate With Teva for Fasinumab Drug (REGN, TEVA) (NASDAQ:REGN) - September 21 at 11:03 AM logoRegeneron Pharmaceuticals Inc (REGN) Affirmed at Buy by Roth Capital: Here's Why (NASDAQ:REGN) - September 21 at 11:03 AM logoRegeneron Pharmaceuticals (REGN) Presents at Bank of America Merrill Lynch 2016 Global Healthcare Conference - Slideshow (NASDAQ:REGN) - September 21 at 11:03 AM logoTeva and Regeneron to commercialise Fasinumab for chronic pain (NASDAQ:REGN) - September 20 at 12:17 PM logoStock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab (NASDAQ:REGN) - September 20 at 12:17 PM
News IconHigh Market Cap Stock of the Day – Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) (NASDAQ:REGN) - September 19 at 6:56 PM
News IconIs Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a large market cap stock a smart buy? (NASDAQ:REGN) - September 17 at 6:30 PM
News IconA look at a High Market Cap Stock: Regeneron Pharmaceuticals, Inc ... - The Daily Leicester (NASDAQ:REGN) - September 17 at 11:28 AM logoREGENERON PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:REGN) - September 14 at 7:07 PM logoRegeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors - PR Newswire (press release) (NASDAQ:REGN) - September 14 at 11:24 AM logoRegeneron Pharmaceuticals, Inc. – Value Analysis (NASDAQ:REGN) : September 13, 2016 (NASDAQ:REGN) - September 14 at 11:24 AM
News IconInvestor Flash: Earnings and Target Review on Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Post News (NASDAQ:REGN) - September 13 at 11:54 AM
News IconIntraday Active Biotech Stocks News: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Champions Oncology, Inc ... - The Voice Registrar (NASDAQ:REGN) - September 12 at 11:38 AM
News IconRegeneron Pharmaceuticals Inc. (NASDAQ: REGN) Neutral Rating Reiterated at Piper Jaffray Cos. - BNB Daily (blog) (NASDAQ:REGN) - September 12 at 11:38 AM logoRegeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : REGN-US : September 12, 2016 (NASDAQ:REGN) - September 12 at 11:38 AM logoRegeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors (NASDAQ:REGN) - September 12 at 11:38 AM
News IconSusquehanna International Group Llp buys $55446842 stake in Regeneron Pharmaceuticals Inc (REGN) - National Daily Press (NASDAQ:REGN) - September 11 at 11:00 AM
News IconAlexion Pharmaceuticals Inc. (ALXN) EVP Carsten Thiel Sells 1000 Shares (NASDAQ:REGN) - September 9 at 6:38 PM
News IconRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) To Report September 2016 Results - The Voice Registrar (NASDAQ:REGN) - September 9 at 11:46 AM
News IconUpdate on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for the day (NASDAQ:REGN) - September 7 at 7:07 PM logoA $14,000 Price Tag For A Cholesterol Drug Can Be A Bargain (NASDAQ:REGN) - September 6 at 11:48 AM logoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Is Expected To Post EPS Of $2.24 (NASDAQ:REGN) - September 5 at 11:04 AM logoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Is Expected To Post EPS Of $2.24 - (NASDAQ:REGN) - September 4 at 6:14 PM
News IconA look at a High Market Cap Stock: Regeneron Pharmaceuticals, Inc., REGN - The Daily Leicester (NASDAQ:REGN) - September 1 at 6:57 PM logoRegeneron Announces Upcoming 2016 Investor Conference Presentations (NASDAQ:REGN) - September 1 at 10:10 AM
News IconHC Stocks in the Rumor - ImmunoGen, Inc. (NASDAQ:IMGN), Regeneron Pharmaceuticals Inc (NASDAQ:REGN) - share market updates (press release) (NASDAQ:REGN) - August 31 at 12:14 PM logoBiotech: In Unfamiliar Territory? (NASDAQ:REGN) - August 31 at 12:14 PM logoWhat Are Analysts’ Recommendations for Regeneron in 2016? (NASDAQ:REGN) - August 31 at 12:14 PM logoRegeneron’s Valuation Multiples Compared to Its Peers (NASDAQ:REGN) - August 31 at 12:14 PM


Regeneron Pharmaceuticals (NASDAQ:REGN) Chart for Thursday, September, 29, 2016

Last Updated on 9/29/2016 by Staff